Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Reclassification of giraffe status pivotal in public action, says UFS researcher
2016-12-08

Description: Reclassification of giraffe status  Tags: Reclassification of giraffe status  

Dr Francois Deacon, specialised researcher
in the Department of Animal, Wildlife, and
Grassland Sciences at the University of the Free State.
Photo: Supplied

Great news for those who care about the conservation of giraffes is today’s (8 December 2016) announcement by the International Union for the Conservation of Nature (IUCN) that giraffes are now classified as ‘Vulnerable’. The species, formerly classified as ‘Least Concern’ on the IUCN Red List — an index on the likelihood of extinction of animals worldwide — is threatened with extinction.

“Until recently, few people were aware of the situation facing giraffes. It is time to show the world giraffe numbers are in danger. This reclassification by the IUCN is pivotal to get the public to stand up and take action for giraffes,” said Dr Francois Deacon, specialised researcher in the Department of Animal, Wildlife, and Grassland Sciences at the University of the Free State (UFS).

Research is essential to develop effective conservation plans for a species

Key to this announcement was the status report submitted by Dr Deacon. He was the lead author responsible for the submission of the Southern African Giraffe subspecies (Giraffa camelopardalis giraffa) status report that was part of the larger species report submitted for review by the (IUCN). The UFS has been doing many research projects in the past couple of years on giraffe-related issues and topics to address this problem.

The UFS is one of only a few universities in Africa that is committed to studying giraffes to ensure the conservation of this species for generations to come.

“The reclassification of giraffes to ‘Vulnerable’
status, by the IUCN, is pivotal to get the public
to stand up and take action for giraffes.”

A 40% decline in the giraffe population over the past two decades is proof that the longnecks are officially in trouble. According to Dr Deacon, this rate of decline is faster than that of the elephant or rhino. The main reasons for the devastating decline are habitat loss, civil unrest and illegal hunting.

Dr Deacon, pioneer in the use of GPS technology to study giraffes and their natural habitat, said “This vulnerability clearly stipulates we are quickly losing grip on our last few natural populations”. He and a team of researchers at the UFS in South Africa are leading various research and conservation projects to help save the last remaining giraffes in Africa.

Giraffes moved from ‘least concern’ to ‘vulnerable’ on the Red List

The IUCN, a health check for our planet, is the highest level at which decision-makers can prove how many species (fauna or flora) are surviving or not. The update from ‘Least Concern’ to ‘Vulnerable’ on the Red List was released at the 13th Conference of the Parties to the Convention on Biological Diversity in Cancun, Mexico.

A wildlife documentary, Last of the Longnecks clearly shows how the number of giraffes has plummeted in the past two decades from 154 000 to fewer than 98 000 today — with numbers of some giraffes, such as Kenya’s reticulated giraffe, declining by as much as 80%.  

Any individual or institution that wants to make a contribution relating to giraffe research can contact Dr Deacon at the UFS on deaconf@ufs.ac.za.

 

In other media:

Announcement on BBC news: http://www.bbc.co.uk/news/science-environment-38240760
Time: http://time.com/3622344/giraffe-extinction/
The Telegraph: http://www.telegraph.co.uk/science/2016/12/08/giraffes-now-facing-extinction-warn-conservationists/
ABC News: http://abcnews.go.com/International/giraffes-danger-extinction-numbers-dropped/story?id=27334959
theguardian: https://www.theguardian.com/environment/2016/dec/08/giraffe-red-list-vulnerable-species-extinction
Aol: http://www.aol.co.uk/news/2016/12/07/giraffes-in-danger-of-extinction-as-population-plunges-by-up-to/  

 

Former articles:

18 November 2016: Studies to reveal correlation between terrain, energy use, and giraffe locomotion
23 August 2016:
Research on locomotion of giraffes valuable for conservation of this species
9 March 2016:
Giraffe research broadcast on National Geographic channel
18 September 2015:
Researchers reach out across continents in giraffe research
29 May 2015:
Researchers international leaders in satellite tracking in the wildlife environment

 



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept